Alloimmune thrombocytopenia

Platelets

Volumn , Issue , 2007, Pages 971-984

  Kaplan, Cecile ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884806641     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50815-6     Document Type: Chapter

References (139)

1. Harrington W.J., Sprague C.C., Minnich V., et al. Immunologic mechanisms in idiopathie neonatal thrombocytopenic purpura. Ann Intern Med 1953, 38:433-469.
2. Shulman N.R., Aster R.H., Leitner A., et al. A new syndrome of post-transfusion immunologic purpura. J Clin Invest 1960, 39:1028-1029.
3. Levine P., Burnham L., Katzin E.M., et al. The role of iso-immunization in the pathogenesis of erythroblastosis fetalis. Am J Obstet Gynecol 1941, 42:925-927.
4. Mueller-Eckhardt C., Kiefel V., Grubert A., et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989, i:363-366.
5. Kaplan C., Forestier F., Daffos F., et al. Management of fetal and neonatal alloimmune thrombocytopenia. Transfus Med Rev 1996, 10:233-240.
6. Hohlfeld P., Forestier F., Kaplan C., et al. Fetal thrombocytopenia: A retrospective survey of 5,194 fetal blood samplings. Blood 1994, 84:1851-1856.
7. Dreyfus M., Kaplan C., Verdy E., et al. Frequency of immune thrombocytopenia in newborns: A prospective study. Blood 1997, 89:4402-4406.
8. Kaplan C., Daffos F., Forestier F., et al. Current trends in neonatal alloimmune thrombocytopenia diagnosis and therapy. Platelet immunology: Fundamental and clinical aspects 1991, Vol. 206:267-278. John Libbey-Eurotex/ed.INSERM, Paris. C. Kaplan-Gouet, N. Schlegel, C. Salmon, J. Mac Gregor (Eds.).
9. Pahal G.S., Jauniaux E., Kinnon C., et al. Normal development of human fetal hematopoiesis between eight and seventeen weeks gestation. Am J Obstet Gynecol 2000, 183:1029-1034.
10. Forestier F., Daffos F., Galacteros F., et al. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986, 20:342-346.
11. Castle V., Andrew M., Kelton J., et al. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986, 108:749-755.
12. Durand-Zaleski I., Schlegel N., Blum-Boisgard C., et al. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: A prospective comparison of effectiveness and costs. Am J Perinatol 1996, 13:423-431.
13. Williamson L.M., Hackett G., Rennie J., et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PLA1, Zwa) as determined by antenatal screening. Blood 1998, 92:2280-2287.
14. Davoren A., McParland P., Barnes C.A., et al. Neonatal alloimmune thrombocytopenia in the Irish population: A discrepancy between observed and expected cases. J Clin Pathol 2002, 55:289-292.
15. Bussel J.B. Neonatal alloimmune thrombocytopenia (NAIT): A prospective case accumulation study [abstract]. Pediatr Res 1988, 23:337a.
16. Curtis B.R., Edwards J.T., Hessner M.J., et al. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000, 96:1574-1581.
17. Cooling L.L.W., Kelly K., Barton J., et al. Determinants of ABH expression on human blood platelets. Blood 2005, 105:3356-3364.
18. Taaning E. HLA antibodies and fetomaternal alloimmune thrombocytopenia: Myth or meaningful?. Transfus Med Rev 2000, 14:275-280.
19. Tanaka T., Umesaki N., Nishio J., et al. Neonatal thrombocytopenia induced by maternal anti-HLA antibodies: A potential side effect of allogenic leukocyte immunization for unexplained recurrent aborters. J Reprod Immun 2000, 46:51-57.
20. Kaplan C., Patereau C., Reznikoff-Etievant M.F., et al. Antenatal PLA1 typing and detection of GP IIb-IIIa complex. Br J Haematol 1985, 60:586-588.
21. Gruel Y., Boizard B., Daffos F., et al. Determination of platelet antigens and glycoproteins in the human fetus. Blood 1986, 68:488-492.
22. Jaegtvik S., Husebekk A., Aune B., et al. Neonatal alloimmune thrombocytopenia due to anti HPA-1a antibodies: The level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG 2000, 107:691-694.
23. Giovangrandi Y., Daffos F., Kaplan C., et al. Very early intracranial haemorrhage in alloimmune thrombocytopenia. Lancet 1990, 336:310.
24. Firan M., Bawdon R., Radu C., et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 2001, 13:993-1002.
25. Ghetie V., Ward E.S. FcRn: The MHC class Irelated receptor that is more than an IgG transporter. Immunol Today 1997, 18:592-598.
26. Yoshida M., Claypool S.M., Wagner J.S., et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004, 20:769-783.
27. Horsewood P., Kelton J.G. Macrophagemediated cell destruction. Immunology of transfusion medicine 1993, 435-464. Marcel Dekker, New York. G. Garratty (Ed.).
28. Raretch J.V., Lanier L.L. Immune inhibitory receptors. Science 2000, 290:84-89.
29. Lin S.Y., Kinet J.P. Immunology: Giving inhibitory receptors a boost. Science 2001, 291:445-446.
30. Wiener E., Abeyakoon O., Benchetrit G., et al. Anti-HPA-1a-mediated platelet phagocytosis by monocytes in vitro and its inhibition by Fc gamma receptor (FcγR) reactive reagents. Eur J Haematol 2003, 70:67-74.
31. Warwick R.M., Vaughan J., Murray N., et al. In vitro culture of colony forming unit-megakaryocyte (CFUMK) in fetal alloimmune thrombocytopenia. Br J Haematol 1994, 88:874-877.
32. Miyazaki R., Ogata H., Iguchi T., et al. Comparative analyses of megakaryocytes derived from cord blood and bone marrow. Br J Haematol 2000, 108:602-609.
33. von dem Borne A.E.G.K.R., Kaplan C., Minchinton R. Nomenclature of human platelet alloantigens. Blood 1995, 85:1409-1410.
34. Metcalfe P., Watkins N.A., Ouwehand W.H., et al. Nomenclature of human platelet antigens. Vox Sang 2003, 85:240-245.
35. Simsek S., Faber N.M., Bleeker P.M., et al. Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis. Blood 1993, 81:835-840.
36. Liu T.C., Shih M.C., Lin C.L., et al. Gene frequencies of the HPA-1 to HPA-8w platelet antigen alleles in Taiwanese, Indonesian, and Thai. Ann Hematol 2002, 81:244-248.
37. Shih M.C., Liu T.C., Ling Lin I., et al. Gene frequencies of the HPA-1 to HPA-13, Oe and Gov platelet antigen alleles in Taiwanese, Indonesian, Filipino and Thai populations. Internat J Molec Med 2003, 12:609-614.
38. Halle L., Bach K.H., Martageix C., et al. Eleven human platelet systems studied in the Vietnamese and Ma'ohis Polynesian populations. Tissue Antigens 2004, 63:34-40.
39. Halle L., Bigot A., Mulen-Imandy G., et al. HPA polymorphism in sub-Saharan African populations: Beninese, Cameroonians, Congolese, and Pygmies. Tissue Antigens 2005, 65:295-298.
40. Kaplan C., Morel-Kopp M.C., Kroll H., et al. HPA-5b (Bra) neonatal alloimmune thrombocytopenia -Clinical and immunological analysis of 39 cases. Br J Haematol 1991, 78:425-429.
41. Glade-Bender J., McFarland J.G., Kaplan C., et al. Anti-HPA-3a induces severe neonatal alloimmune thrombocytopenia. J Pediatr 2001, 138:862-867.
42. Ohto H., Miura S., Ariga H., et al. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med 2004, 14:399-408.
43. Peyruchaud O., Bourre F., Morel-Kopp M.C., et al. HPA-10wb (Laa): Genetic determination of a new plateletspecifi c alloantigen on glycoprotein IIIa and its expression in cos-7 cells. Blood 1997, 89:2422-2428.
44. Kroll H., Kiefel V., Santoso S., et al. Sra, a private platelet antigen on glycoprotein-IIIa associated with neonatal alloimmune thrombocytopenia. Blood 1990, 76:2296-2302.
45. Berry J.E., Murphy C.M., Smith G.A., et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 2000, 110:735-742.
46. Jallu V., Meunier M., Brement M., Kaplan C. A new platelet polymorphism Duva+, localized within the RGD binding domain of glycoprotein IIIa, is associated with neonatal thrombocytopenia. Blood 2002, 99:4449-4456.
47. Santoso S., Kiefel V., Richter I.G., et al. A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the beta (3) integrin: The Oe (a) alloantigen in neonatal alloimmune thrombocytopenia. Blood 2002, 99:1205-1214.
48. Davoren A., Curtis B.R., Aster R.H., et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004, 44:1220-1225.
49. Kroll H., Yates J., Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: Characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion 2005, 45:353-358.
50. Kaplan C., Porcelijn L., Vanlieferinghen P.H., et al. Anti-HPA-9bw (Maxa) feto-maternal alloimmunization, a clinically severe neonatal thrombocytopenia: Difficulties in diagnosis and therapy, report on 8 families. Transfusion 2005, 45:1799-1803.
51. Ertel K., Al-Tawil M., Santoso S., et al. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005, 45:366-373.
52. Curtis B.R., Ali S., Glazier A.M., et al. Isoimmunization against CD36 (glycoprotein IV): Description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002, 42:1173-1179.
53. Léticée N., Kaplan C., Lémery D. Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: Is there a foetal risk?. Eur J Obstet Gynecol Reproduc Biol 2005, 121:139-142.
54. Semple J.W., Freedman J. Recipient antigenprocessing pathways of allogeneic platelet antigens: Essential mediators of immunity. Transfusion 2002, 42:958-961.
55. Semple J.W., Bang K.W.A., Speck E.R., et al. Recipient mechanisms of alloimmunity: Antigen processing mediates IgG immunity against donor platelets. Molecular biology in blood transfusion 2000, 135-145. Kluwer Academic, Dordrecht, Netherlands. C. Smit Sibinga, H.G. Klein (Eds.).
56. Semple J.W., Freedman J. The basic immunology of platelet-induced alloimmunisation. Current Issues in Platelet Transfusion therapy and platelet alloimmunity 1999, 77-101. AABB Press, Bethesda, MD. T.S. Kickler, J.H. Herman (Eds.).
57. Valentin N., Vergracht A., Bignon J.D., et al. HLA DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990, 27:73-79.
58. L'Abbé D., Tremblay L., Filion M., et al. Alloimmunization to platelet antigen HPA-1a (PlA1) is strongly associated with both HLA-DR30101 and HLA-DQB10201. Hum Immunol 1992, 34:107-114.
59. Kuijpers R.W., von dem Borne A.E., Kiefel V., et al. Leucine33-proline33 substitution in human platelet glycoprotein IIIa determines HLA-DRw52a (Dw24) association of the immune response against HPA-1a (Zwa/PLA1) and HPA-1b (Zwb/PLA2). Hum Immunol 1992, 34:253-356.
60. Semana G., Zazoun T., Alizadeh M., et al. Genetic susceptibility and anti-human platelet antigen 5b alloimmunization: Role of HLA class II and TAP genes. Hum Immunol 1996, 46:114-119.
61. Sayeh E., Aslam R., Speck E.R., et al. Immune responsiveness against allogeneic platelet transfusions is determined by the recipent's major histocompatibility complex class II phenotype. Transfusion 2004, 44:1572-1578.
62. Wu S., Maslanka K., Gorski J. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: A model for unidirectional alloimmune responses. J Immunol 1997, 158:3221-3226.
63. Goldberger A., Kolodziej M., Poncz M., et al. Effect of single amino acid substitutions on the formation of PL alloantigenetic and Bakepitopes. Blood 1991, 78:681-687.
64. Maslanka K., Yassai M., Gorski J. Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. J Clin Invest 1996, 98:1802-1808.
65. Panzer S., Auerbach L., Cechova E., et al. Maternal alloimmunization against fetal platelet antigens: A prospective study. Br J Haematol 1995, 90:655-660.
66. Valentin N., Visentin G.P., Newman P.J. Involvement of the cystein-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: Evidence for heterogeneity in the humoral response. Blood 1995, 85:3028-3033.
67. Morel-Kopp M.C., Daviet L., McGregor J., et al. Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Blood Coagul Fibrinolysis 1996, 7:144-146.
68. Harrison C.R., Curtis B.R., McFarland J.G., et al. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. Transfusion 2003, 43:1398-1402.
69. Kaplan C., Daffos F., Forestier F., et al. Management of alloimmune thrombocytopenia: Antenatal diagnosis and in utero transfusion of maternal platelets. Blood 1988, 72:340-343.
70. Spencer J.A., Burrows R.F. Feto-maternal alloimmune thrombocytopenia: A literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001, 41:45-55.
71. Murphy M.F., Waters A.H., Doughty H.A., et al. Antenatal management of fetomaternal alloimmune thrombocytopenia -report of 15 affected pregnancies. Transfus Med 1994, 4:281-292.
72. Stanworth S.J., Hackett G.A., Williamson L.M. Fetomaternal alloimmune thrombocytopenia presenting antenatally as hydrops fetalis. Prenat Diagn 2001, 21:423-424.
73. Chakravorty S., Murray N., Roberts I. Neonatal thrombocytopenia. Early Hum Dev 2005, 81:35-41.
74. Bussel J.B., Zacharoulis S., Kramer K., et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005, 45:176-183.
75. Kiefel V., Santoso S., Weisheit M., et al. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): A new tool for the identification of platelet-reactive antibodies. Blood 1987, 70:1722-1726.
76. McMillan R. Antigen-specific assays in immune thrombocytopenia. Transfus Med Rev 1990, 4:136-143.
77. Panzer S., Kaplan C. On behalf of the platelet and granulocyte workshop ISBT: Report on the 1997 international society of blood transfusion workshop for genotyping of platelet alloantigens. Transfus Med 1998, 8:125-128.
78. Goldman M., Trudel E., Richard L. Report on the Eleventh International Society of Blood Transfusion Platelet Genotyping and Serology Workshop. Vox Sang 2003, 85:149-155.
79. Jallu V., Bianchi F., Kaplan C. Fetal-neonatal alloimmune thrombocytopenia and unexpected Glanzmann thrombasthenia carrier: Report of two cases. Transfusion 2005, 45:550-553.
80. Curtis B.R., Bussel J.B., Manco-Johnson M.J., et al. Fetal and neonatal alloimmune thrombocytopenia in pregnancies involving in vitro fertilization: A report of four cases. Am J Obstet Gynecol 2005, 192:543-547.
81. Hurd C., Lucas G. Human platelet antigen genotyping by PCR-SSP in neonatal/fetal alloimmune thrombocytopenia. Pediatric hematology: Methods and protocols 2004, Vol. 91:71-78. Humana Press, Totowa, NJ. N.J. Goulden, C.G. Steward (Eds.).
82. Gautier E., Benachi A., Giovangrandi Y., et al. Fetal RhD genotyping by maternal serum analysis: A twoyear experience. Am J Obstet Gynecol 2005, 192:666-669.
83. Lee K., Beaujean F., Bierling P. Treatment of severe fetomaternal alloimmune thrombocytopenia with compatible frozen-thawed platelet concentrates. Br J Haematol 2002, 117:482-483.
84. Ranasinghe E., Walton J.D., Hurd C.M., et al. Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 2001, 113:40-42.
85. Allen D.L., Samol J., Benjamin S., et al. Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med 2004, 14:409-417.
86. Win N. Provision of Random-Donor Platelets (HPA-1a Positive) in neonatal alloimmune thrombocytopenia due to anti HPA-1a alloantibodies. Vox Sang 1996, 71:130-131.
87. Massey G.V., McWilliams N.B., Mueller D.G., et al. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987, 111:133-135.
88. Radder C.M., Brand A., Kanhai H.H. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001, 185:683-688.
89. Bussel J.B. Alloimmune thrombocytopenia in the fetus and newborn. Semin Thromb Hemost 2001, 27:245-252.
90. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 2002, 16:69-72.
91. Birchall J.E., Murphy M.F., Kaplan C., et al. On behalf of the European fetomaternal alloimmune thrombocytopenia study group: European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 2003, 122:275-288.
92. Rayment R., Brunskill S.J., Stanworth S., et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2005, 1:CD004226.
93. Blanchette V.S., Semple J.W., Freedman J. Intravenous immunoglobulin and Rh immunoglobulin as immunomodulators of autoimmunity to blood elements. Autoimmune disorders of blood 1996, 35-77. AABB Press, Bethesda. L.E. Silberstein (Ed.).
94. Salama A., Mueller-Eckhardt C., Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia: Competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells?. Lancet 1983, 2:193-195.
95. Crow A., Song S., Semple J.W., et al. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001, 115:679-686.
96. Berchtold P., Dale G.L., Tani P., et al. Inhibition of autoantibody binding to platelet glycoprotein IIb-IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989, 74:2414-2417.
97. Rossi F., Kazatchkine M.D. Anti idiotypes against autoantibodies in pooled normal human polyspecific. Ig J Immunol 1989, 143:4104-4109.
98. McKenzie S.E., Taylor S.M., Malladi P., et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: A transgenic mouse model. J Immunol 1999, 162:4311-4318.
99. Samuelsson A., Towers T.L., Ravetch J.V. Antiinfl ammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
100. Ravetch J.V., Bolland S. IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290.
101. Lazarus A.H., Freedman J., Semple J.W. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): Mechanisms of action. Transfus Sci 1998, 19:289-294.
102. Bowman J., Harman C., Mentigolou S., et al. Intravenous fetal transfusion of immunoglobulin for alloimmune thrombocytopenia. Lancet 1992, 340:1034-1035.
103. Hansen R.J., Balthasar J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002, 100:2087-2093.
104. Nieswandt B., Bergmeier W., Rackebrandt K., et al. Identification of critical anti-gen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000, 96:2520-2527.
105. Kurz M., Stockelle E., Eichelberger B., et al. IgG titer, subclass, and light-chain phenotype of pregnancyinduced HPA-5b antibodies that cause or do not cause neonatal alloimmune thrombocytopenia. Transfusion 1999, 39:379-382.
106. Radder C.M., Beekhuizen H., Kanhai H.H., et al. Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells. Clin Exp Immunol 2004, 137:216-222.
107. Paidas M.J., Berkowitz R.L., Lynch L., et al. Alloimmune thrombocytopenia: Fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995, 172:475-479.
108. Engelfriet C.P., Reesink H.W., Kroll H., et al. International forum: Prenatal management of alloimmune thrombocytopenia of the fetus. Vox Sang 2003, 84:142-149.
109. Radder C.M., Brand A., Kanhai H.H. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 2003, 84:318-325.
110. Radder C.M., de Hann M.J., Brand A., et al. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev 2004, 80:65-76.
111. Radder C.M., Roelen D.L., van de Meers-Prins E.M., et al. The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2004, 191:815-820.
112. Doughty H.A., Murphy M.F., Metcalfe P., et al. Antenatal screening for fetal alloimmune thrombocytopenia: The results of a pilot study. Br J Haematol 1995, 90:321-325.
113. Murphy M.F., Williamson L.M. Antenatal screening for fetomaternal alloimmune thrombocytopenia: An evaluation using the criteria of the UK national screening committee. Br J Haematol 2000, 111:726-732.
114. Murphy M.F., Williamson L.M., Urbaniak S.J. Antenatal screening for fetomaternal alloimmune thrombocytopenia: Should we be doing it?. Vox Sang 2002, 83(suppl. 1):409-416.
115. Ni H., Chen P., Spring C.M., et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006, 107:2976-2983.
116. Zucker M.B., Ley A.B., Borrelli J., et al. Thrombocytopenia with a circulating platelet agglutinin, platelet lysin, and a clot retraction inhibitor. Blood 1959, 14:148-161.
117. van Loghem J.J., Dorfmeijer H., van Hart M., et al. Serological and genetical studies on a platelet antigen (Zw). Vox Sang 1959, 4:161-169.
118. Serious Hazards of Transfusion Annual report 2003: Post-transfusion Purpura 2004, 65-66.
119. Mueller-Eckhardt C., Kroll H., Kiefel V., et al. Post-transfusion purpura. Clinical and fundamental aspects 1991, Vol. 206:249-255. John Libbey, Paris. C. Kaplan-Gouet, N. Schlegel, C. Salmon, J. McGregor (Eds.).
120. Warkentin T.E. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005, 127:35S-45S.
121. Lubenow N., Eichler P., Albrecht D., et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia: Report of four cases and review of literature. Thromb Res 2000, 100:115-125.
122. Araujo F., Sa J.J., Araujo V., et al. Post-transfusion purpura vs. heparin-induced thrombocytopenia: Differential diagnosis in clinical practice. Transfus Med 2000, 10:323-324.
123. Wernet D., Sessler M., Dette S., et al. Posttransfusion purpura following liver transplantation. Vox Sang 2003, 85:117-118.
124. Shulman N.R., Aster R.H., Leithner A., et al. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen: A proposed mechanism for thrombocytopenia and its relevance in "autoimmunity.". J Clin Invest 1961, 40:1597-1620.
125. Watkins N.A., Smethurst P.A., Allen D., et al. Platelet αIIbβ3 recombinant autoantibodies from the B-cell repertoire of a post-transfusion purpura patient. Br J Haematol 2002, 116:677-685.
126. McFarland J.G. Detection and identification of platelet antibodies in clinical disorders. Transfus Apher Sci 2003, 28:297-305.
127. Mueller-Eckhardt C., Kiefel V. High-dose IgG for post-transfusion purpura -revisited. Blut 1988, 57:163-167.
128. McFarland J.G. Posttransfusion purpura. Transfusion reactions 2001, 187-212. AABB Press, Bethesda, MD. M.A. Popovsky (Ed.).
129. Loren A.W., Abrams C.S. Efficacy of HPA-1a (PlA1) -negative platelets in a patient with post-transfusion purpura. Am J Hematol 2004, 76:258-262.
130. Godeau B., Fromont P., Bettaieb A., et al. Relapse of posttransfusion purpura after transfusion with frozenthawed red cells. Transfusion 1991, 31:189-190.
131. Ballem P.J., Buskard N.A., Decary F., et al. Posttransfusion purpura secondary to passive transfer of anti-P1A1 by blood transfusion. Br J Haematol 1987, 66:113-114.
132. Brunner-Bolliger S., Kiefel V., Horber F.F., et al. Antibody studies in a patient with acute thrombocytopenia following infusion of plasma containing anti- (PlA1). Am J Hematol 1997, 56:119-121.
133. Warkentin T.E., Smith J.W., Hayward C.P.M., et al. Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). Blood 1992, 79:2480-2484.
134. Boehlen F., Bulla O., Michel M., et al. HPAgenotyping and antiplatelet antibodies in female blood donors. Hematol J 2003, 4:441-444.
135. Bang A., Speck E.R., Blanchette V.S., et al. Recipient humoral immunity against leukoreduced allogeneic platelets is suppressed by aminoguanidine, a selective inhibitor of inducible nitric oxide synthase. Blood 1996, 88:2959-2966.
136. Bang K.W.A., Speck E.R., Blanchette V.S., et al. Unique processing pathways within recipient antigenpresenting cells determine IgG immunity against donor platelet MHC antigens. Blood 2000, 95:1735-1742.
137. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers inflammatory reactions of endothelial cells. Nature 1998, 391:591-594.
138. Büchner K., Henn V., Gräfe M., et al. CD40 ligand is selectively expressed on CD4+ T cells and platelets: Implications for CD40-CD40L signaling in atherosclerosis. J Pathol 2003, 201:288-295.
139. Sayeh E., Sterling K., Speck E., et al. IgG antiplatelet immunity is dependent on an early innate natural killer cell-derived interferonγ response that is regulated by CD8+ T cells. Blood 2004, 103:2705-2709.